News

The Bayer China Hemophilia Treatment Center Development Project is a partnership between Bayer Schering Pharmaceuticals and the Chinese Society of Hematology to improve hemophilia care throughout the country.

The Phase I/II study of ARX201, analyzed 22 adult growth hormone deficiency (AGHD) patients who had not received hGH replacement therapy in the six months prior to the

The six month results from the MIVI III (MIVI III – microplasmin for vitreous injection) trial continue to support the one month data previously reported, namely that the

In this new post hoc analysis, kidney function was assessed using estimated glomerular filtration rate (eGFR), as recommended by the National Kidney Foundation. Increases in eGFR indicate improved

Existing investor, Greatbatch, a developer of medical devices, also participated in the equity portion of the round that will provide between $11 million and $13.5 million plus the

The Phase IIb study is designed to evaluate the safety and efficacy of QR-333, a topical formulation designed to offer physicians and patients an effective, easy to administer,

The Ovature trial is a major multi-center international Phase III clinical trial of orally-administered investigational drug phenoxodiol in combination with carboplatin in women with advanced ovarian cancer resistant

In his new role, Mr Garbarini is responsible for Ferring’s two marketed products in these areas, euflexxa (1% sodium hyaluronate) for the pain caused by knee osteoarthritis, and

Under terms of the agreement, DAW will receive a dispensing fee for each prescription dispensed in exchange for providing comprehensive clinical pharmacy and pharmacy management services. Management estimates